|
Louis C. Bock, has served as a member of our board of directors since September 2000. Mr. Bock is a Managing Director of BA Venture Partners. Mr. Bock joined BA Venture Partners in September 1997 from Gilead Sciences, Inc., a biopharmaceutical company, where he held positions in research, project management, business development and sales from September 1989 to September 1997. Prior to Gilead, Mr. Bock was a research associate at Genentech, Inc. from November 1987 to September 1989. He currently serves on the Board of Directors of Ascenta Therapeutics, diaDexus Inc., Horizon Therapeutics, Orexigen Therapeutics and Zogenix. He is responsible for BAVP investments in Seattle Genetics (NASDAQ: SGEN), Somaxon Pharmaceuticals (NADAQ: SMX) and Prestwick Pharmaceuticals. Mr. Bock received his B.S. in Biology from California State University, Chico and an M.B.A. from California State University, San Francisco. | 